Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements

Many unexpected problems have resulted from the unprecedented coronavirus disease 2019 (COVID-19) pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal D...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yong Eun, Lee, Yoo Jin, Chang, Ji Young, Song, Hyun Joo, Kim, Duk Hwan, Yang, Young Joo, Kim, Byung Chang, Lee, Jae Gon, Yang, Hee Chan, Choi, Miyoung, Kim, Seong-Eun, Myung, Seung-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650326/
https://www.ncbi.nlm.nih.gov/pubmed/34974675
http://dx.doi.org/10.5217/ir.2021.00111
Descripción
Sumario:Many unexpected problems have resulted from the unprecedented coronavirus disease 2019 (COVID-19) pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.

Ejemplares similares